• SEC Filings

On June 25, 2018, Mark S. Gold, M.D. tendered his resignation as a member of the board of directors of ViewRay, Inc. (the “Company”), and David Bonita, M.D., did not stand for reelection at the Company’s Annual Meeting of Stockholders and resigned at the end of his regular term.Each of Dr. Gold’s and Dr. Bonita’s decisions to resign had previously been disclosed by the Company and were not due to any disagreement with the Company regarding any matter related to the Company’s operations, policies or practices.

On June 25, 2018, ViewRay, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at the Company’s offices located at 815 E. Middlefield Road, Mountain View, California 94043. Only stockholders of record at the close of business on April 26, 2018, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 75,084,219 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 68,333,364 shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 30, 2018.

Set forth below, with respect to each such matter, are the number of votes cast for or against, the number of votes withheld and the number of broker non-votes.

Proposal No.1 – Election of Directors

The Company’s stockholders elected each of Caley Castelein, M.D., Brian K. Roberts and Scott Huennekens to serve as Class III directors of the Company until the 2021 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or until such director's earlier death, resignation or removal.

Proposal No.2 – Ratification of Selection of Independent Registered Accounting Firm

The Company’s stockholders ratified the selection, by the Audit Committee of the Board of Directors, of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2018.

About VIEWRAY, INC. (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.